The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and GLP-1 (weight-loss)…
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery process is…
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA | NVDA Price Prediction) to the forefront of the industry.…
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs…
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists like Ozempic, Wegovy,…
Remember when a stock becoming valued at $1 trillion was a big thing? The first company to do so was Apple (NASDAQ:AAPL | AAPL Price Prediction) back in 2018. Now there are…
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Apple, AT&T, Cenovus Energy, Dollar General, Dynatrace, FedEx, Molson Coors Beverage, NiSource, Uber Technologies and Vale.
Wednesday's top analyst upgrades and downgrades included Albemarle, Boeing, Ingersoll-Rand, Novo Nordisk, Nutrien, Palantir Technologies, PayPal, Shoals Technologies, Shopify, Skyworks Solutions, Walmart and XPO.
Tuesday’s additional top analyst upgrades and downgrades were on BHP, Booz Allen Hamilton, Devon Energy, Mirati Therapeutics, Novo Nordisk, NRG Energy and more.
